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Abstract
Background: Terminal duct lobular units (TDLUs) are the primary structures from which breast cancers and their
precursors arise. Decreased age-related TDLU involution and elevated mammographic density are both correlated
and independently associated with increased breast cancer risk, suggesting that these characteristics of breast
parenchyma might be linked to a common factor. Given data suggesting that increased circulating levels of insulin-
like growth factors (IGFs) factors are related to reduced TDLU involution and increased mammographic density, we
assessed these relationships using validated quantitative methods in a cross-sectional study of women with benign
breast disease.
Methods: Serum IGF-I, IGFBP-3 and IGF-I:IGFBP-3 molar ratios were measured in 228 women, ages 40-64, who
underwent diagnostic breast biopsies yielding benign diagnoses at University of Vermont affiliated centers. Biopsies
were assessed for three separate measures inversely related to TDLU involution: numbers of TDLUs per unit of
tissue area (“TDLU count”), median TDLU diameter (“TDLU span”), and number of acini per TDLU (“acini count”).
Regression models, stratified by menopausal status and adjusted for potential confounders, were used to assess the
associations of TDLU count, median TDLU span and median acini count per TDLU with tertiles of circulating IGFs.
Given that mammographic density is associated with both IGF levels and breast cancer risk, we also stratified these
associations by mammographic density.
Results: Higher IGF-I levels among postmenopausal women and an elevated IGF-I:IGFBP-3 ratio among all
women were associated with higher TDLU counts, a marker of decreased lobular involution (P-trend = 0.009
and <0.0001, respectively); these associations were strongest among women with elevated mammographic density
(P-interaction <0.01). Circulating IGF levels were not significantly associated with TDLU span or acini count per TDLU.
(Continued on next page)
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Conclusions: These results suggest that elevated IGF levels may define a sub-group of women with high
mammographic density and limited TDLU involution, two markers that have been related to increased breast
cancer risk. If confirmed in prospective studies with cancer endpoints, these data may suggest that evaluation
of IGF signaling and its downstream effects may have value for risk prediction and suggest strategies for
breast cancer chemoprevention through inhibition of the IGF system.
Background
Terminal duct lobular units (TDLUs) comprise the
secretory units of the breast and are the structures from
which most breast cancers and their precursors arise.
Microscopically, TDLUs consist of terminal ducts and
substructures referred to as acini. With aging, TDLUs
involute, which results in reduced acini content per
TDLU (i.e., decreased TDLU epithelial sub-structures),
shorter TDLU span and eventually lower TDLU num-
bers. Data suggest that reduced age-related TDLU invo-
lution among women with benign breast disease is a
marker of increased breast cancer risk [1–5]. However,
factors and mechanisms that account for the substantial
observed inter-individual variation among women are
not well-described [6]. There are several ways to deter-
mine the degree of lobular involution of the breast in-
cluding counting the number of TDLUs or acini within
a TDLU structure [6], measuring the diameter of lobules
[6], or characterizing lobule type [5]. Assessing factors
associated with TDLU involution, as assessed qualita-
tively or quantitatively, could elucidate mechanisms re-
lated to breast cancer risk and suggest strategies for risk
prediction following a benign breast biopsy or preventive
strategies that accelerate the involution process. The
insulin-like growth factor (IGF) system represents a
promising candidate pathway that may influence breast
cancer risk by modulating TDLU involution.
In rodent models, the IGF system interacts with hor-
monal and non-hormonal pathways to influence nor-
mal breast development over time, including breast
development during puberty, pregnancy, and the post-
lactational involution that accompanies weaning [7–9].
In women, associations between circulating IGF-I con-
centrations and breast cancer risk have been robust. A
recent pooled analysis of data from approximately
20,000 pre- and postmenopausal women included in
17 prospective studies concluded that elevated IGF-I
was associated with increased breast cancer risk, and
this association did not vary significantly by meno-
pausal status at blood collection [10]. Nonetheless,
poor reproducibility between IGF assays, small effect
sizes, and weaker effects for prospective studies as
compared with case-control studies have led to diver-
ging views about the importance of the IGF system in
breast cancer [11, 12].
In the Nurses’ Health Study, elevated IGF-I and a
higher IGF-I:IGFBP-3 ratio were associated with de-
creased TDLU involution, based on visual assessment
[13]. In the same study, increased IGF receptor staining
in TDLUs of women with benign proliferative breast dis-
ease was associated with increased risk of subsequent
breast cancer. Similarly, we hypothesize that higher
serum levels of IGF-I and the IGF-I:IGFBP-3 ratio are
associated with lower levels of TDLU involution among
women with benign breast disease. Further, we suggest
that IGFs exert their most important effects on normal
breast tissue, early in the process of breast cancer devel-
opment; IGFs, therefore, may influence breast cancer
risk indirectly by shaping the molecular histology upon
which other factors act. Thus, assessing the IGF system
and its relationship to breast cancer risk may require an
understanding of its effects on benign breast tissue and
the effects other downstream factors may have on the
at-risk epithelium of the TDLU. We hypothesize that el-
evated mammographic density, a clinical factor associ-
ated with both increased breast cancer risk and
decreased TDLU involution of the breast [1, 14–16],
may be an important complementary cofactor. Specific-
ally, TDLU involution, as assessed histologically, provides
a detailed snapshot of breast structure in a small region of
the breast, whereas mammographic density represents a
global measure of non-fatty tissue, but does not distin-
guish between epithelium and non-fatty stroma.
To assess the possible associations between the IGF
system and TDLU involution, we evaluated serum levels
of IGF-I, IGFBP-3 and the molar ratio of IGF-I:IGFBP-3
among women with benign breast disease in relation to
three standardized, reproducible quantitative measures
that are inversely related to TDLU involution [6]: num-
bers of TDLUs per unit of tissue area (TDLU count), the
diameter of the TDLU (TDLU span), and acini counts
per TDLU. Further, we assessed the potential effect
modification of these associations by mammographic
density.
Methods
Study population
The Breast Radiology Evaluation and Study of Tissues
(BREAST) Stamp Project is a cross-sectional molecular
epidemiologic study of mammographic density in 465
Horne et al. Breast Cancer Research  (2016) 18:24 Page 2 of 12
women ages 40 to 65 years, referred for diagnostic bi-
opsy from 2007 through 2010 at the University of
Vermont (UVM) College of Medicine and its affiliated
academic medical center, the UVM Medical Center
(formerly Fletcher Allen Health Care) [17]. The current
analysis included women in the BREAST Stamp Project
with available serum (>3.2 mL serum available), who
were not using exogenous hormones at the time of bi-
opsy, and who had available quantitative histologic assess-
ment of TDLU involution, resulting in 281 eligible women
for IGF-I and IGFBP-3 serum testing (see below). Of the
281 women with IGF-I and IGFBP-3 measurements, we
further excluded 47 women with breast cancer and 6 with-
out TDLU data, resulting in an analytic sample of 228
women, including 155 premenopausal and 73 postmeno-
pausal women. For 2 of the 228 women, it was unknown
whether they were current users of menopausal hormone
therapy. These women were included in the analytic
population, given that their exclusion did not alter the
study results. Participants provided written informed con-
sent, which included providing access to medical records
and mammographic images; Institutional Review Boards
at the University of Vermont and the National Cancer In-
stitute approved this study.
Study procedures
Women were referred for image-guided breast biopsy
following an abnormal breast imaging examination.
Digital mammographic examinations were performed
with a density phantom, permitting measurement of
percent volumetric mammographic density using single
x-ray absorptiometry (SXA) [18]. For the same digital im-
ages that were selected for SXA analyses, measures of per-
cent dense area were estimated, as described previously
[19, 20], using interactive, computer-assisted thresholding
software comparable to other validated methods [21]. Per-
cent volumetric mammographic density as measured
using SXA has been found to be accurate to equivalent
measures acquired from magnetic resonance imaging
(MRI) of the breast [22], and significantly associated with
breast cancer risk [20, 23]. Density measures used in this
study are from the ipsilateral breast on which the biopsy
was performed and TDLU measures assessed.
Demographic and breast cancer risk factor information
was collected using a self-administered questionnaire (see
sample questionnaire at http://breastscreening.cancer.gov/
[24]) and a supplementary telephone interview. A woman
was considered postmenopausal if menstrual periods had
stopped more than 12 months prior to interview, if she
had undergone bilateral oophorectomy, or if she had
undergone hysterectomy (or gynecologic surgery associ-
ated with cessation of menses) and was 55 years of age or
older; otherwise, a woman was considered premenopausal.
Given the age range of our study population, the
premenopausal subgroup likely contains a mixture of
both pre- and perimenopausal women. For a subset
of premenopausal women with previously measured
serum follicle stimulating hormone (FSH) and estra-
diol levels (n = 105), we identified perimenopausal
women (n = 19) as previously described [25]. Body
mass index (BMI, kg/m2) was computed from mea-
sures of height and weight obtained on the day of the
breast biopsy. Whole blood samples were collected
prior to breast biopsy using standard techniques,
allowed to clot for 30 minutes, and processed at the
UVM General Clinical Research Center. Samples were
centrifuged at 3,000 rpm for 15 minutes, and the
serum and clot fractions were frozen at –80 °C until
shipment to SeraCare Life Sciences (Gaithersburg,
MD, USA), where they were stored in liquid nitrogen.
Laboratory measures of IGF-I and IGFBP-3
IGF-I and IGFBP-3 levels were measured in duplicate in
masked serum samples by enzyme-linked immunosorb-
ent assay (ELISA) (Diagnostic Systems Laboratory
(Webster, TX, USA)) as described previously [26]. Three
quality control (QC) samples (follicular phase, luteal
phase and postmenopausal samples) were measured in
duplicate in a masked fashion with each of the eight
assay batches performed. The mean intra-batch coeffi-
cients of variation (CVs) were 2.7 % for IGF-I and 5.1 %
for IGFBP-3, and the inter-batch CVs were 10.5 % for
IGF-I and 10.5 % for IGFBP-3. Mean IGF-I and IGFBP-3
levels for each subject’s duplicate measurements were
used in the analyses. To approximate the circulating
free, bioactive levels of IGF-I, the molar ratio of IGF-I to
IGFBP-3 was estimated as previously described [27, 28].
Overall and menopausal status-specific tertiles of IGF-I,
IGFBP-3 and their molar ratio were calculated and used
in subsequent association analyses.
Pathology
Ultrasound-guided core needle (14-gauge needle) or
stereotactic-guided vacuum-assisted (9-gauge needle)
breast biopsies were routinely processed as formalin-
fixed paraffin-embedded blocks, which were sectioned
and stained with hematoxylin and eosin (H&E) for
diagnosis. For study purposes, final diagnoses were
categorized as non-proliferative benign breast disease,
proliferative (ductal hyperplasia; sclerosing adenosis),
proliferative with atypia (atypical ductal or lobular
hyperplasia), in-situ, or invasive breast carcinoma based
on review of microscopic sections and surgical pathology
reports. The present analysis was restricted to women
whose biopsy diagnoses were benign (Additional file 1:
Table S1). Digitized images of sections from the target
block were used for analysis of TDLU involution
(described below).
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Histologic assessment of TDLU involution
H&E-stained tissue sections were digitized at × 20 mag-
nification (Aperio ScanScope CS, Vista, CA, USA), and
prepared for web-based viewing and annotation with
Digital Image Hub software (SlidePath/Leica, Dublin,
Ireland). The lasso tool in Digital Image Hub was used
to manually outline and measure total tissue area (mm2)
per section. For women who had multiple benign biopsy
targets, measures from the first biopsy were used (n = 5).
Sections were visually assessed to estimate percentage
fat (0, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95 and
100 %). Normal TDLUs per section were enumerated,
and up to 10 TDLUs were evaluated for maximum
diameter as TDLU span (measured with an electronic
ruler in microns) and categories of acini counts per
TDLU (categories: 1, ≤10; 2, 11–20; 3, 21–30; 4, 31–50;
5, 51–100; and 6, >100) to provide reliable estimates, as
previously described [6]. Median values for each woman
were used as summary measures of TDLU span and
acini count. Overall and menopausal status-specific ter-
tiles of median TDLU span and median category of acini
counts per TDLU were calculated and used in subse-
quent analyses. A previous study demonstrated high
intra-observer agreement (Spearman’s r >0.90) for the
study pathologist (MES) for the TDLU measures [6].
Statistical analysis
Because IGF levels have been shown to differ by meno-
pausal status [10, 29], analyses of associations between
circulating IGF-I or IGFBP-3 levels and TDLU measures
were done for all women combined and women strati-
fied by menopausal status. Circulating IGF levels and
TDLU measures in premenopausal and postmenopausal
women were compared using the Kruskal–Wallis rank
test. Relationships between circulating IGF levels, TDLU
measures and mammographic density were assessed
with Spearman rank correlation; Spearman partial rank
correlation was also estimated after removing the effects
of age and BMI. To account for excess zero TDLU
counts in the study population, multivariable zero-
inflated Poisson (ZIP) regression [30] was used to esti-
mate relative risks (RRs) and 95 % confidence intervals
(CIs) for the relationship between circulating IGF levels
(in tertiles) and number of TDLUs (i.e., TDLU count).
ZIP regression models included tissue area as an offset
to account for differences in biopsy needle gauges.
Potential confounders were identified separately for pre-
and postmenopausal women for inclusion in the multi-
variable models. We also explored inclusion of inter-
action terms in sensitivity analysis. Among all women,
interactions between BMI and menopausal status and
BMI and percent fat on the tissue slide were statistically
significant; however, their inclusion did not alter the
observed RRs, and the most parsimoniously adjusted
model is therefore presented. Among postmenopausal
(but not premenopausal) women, we identified a signifi-
cant interaction between BMI and percent fat on the tis-
sue slide, which was retained in the final model to
improve fit even though its inclusion did not alter re-
sults for the main exposures.
Among women with at least one TDLU, ordinal logis-
tic regression models were used to estimate odds ratios
(ORs) and 95 % CIs for associations between circulating
IGF levels (independent variable, categorized into
tertiles) and the outcomes of median TDLU span and
median category of acini count per TDLU (categor-
ies: 1, ≤10; 2, 11–20; 3, 21–30; 4, 31–50; 5, 51–100;
and 6, >100). For these analyses, adjustment factors
were identified by stepwise selection with an inclusion/
exclusion criterion of P <0.05 and P >0.10, respectively.
The variables that were considered included age at bi-
opsy, BMI, ages at menarche, first birth and menopause
(among menopausal women), parity and percent fat on
the tissue slide. Final models for each analysis are in-
cluded within the respective table footnotes.
We tested for effect modification of the association be-
tween IGF levels and TDLU count by stratifying models
on mammographic density (menopausal-specific tertiles
of percent volumetric density). Stratified analyses were
adjusted for the confounders identified in the main ana-
lysis with the exception of the interaction between
BMI and percent fat on the tissue slide, as its inclusion
yielded similar results, and age at menarche in the
stratum of the highest mammographic density tertile
among postmenopausal women, in order to improve
model convergence. We used the Wald test to compare
the estimates from models stratified by tertiles of
mammographic density to obtain a P value for inter-
action (P-int). Sensitivity analyses using percent dense
mammographic area yielded similar conclusions (data
not shown). In sensitivity analyses, we also restricted
analyses of premenopausal women to those with avail-
able hormone data, excluding potentially perimeno-
pausal women. In addition, we mutually adjusted
models relating IGF-I and IGFBP-3 to TDLU counts
for IGFBP-3 and IGF-I, respectively. Statistical ana-
lyses were conducted using Stata version 11.2 (Statacorp,
College Station, TX, USA), with the exception of the
tests for interaction which were conducted in R version
2.14.1 [31].
Results
Participant characteristics
Overall, 94 % of subjects were white and 68 % were pre-
menopausal. The median age at biopsy for premenopausal
women was 47 years and for postmenopausal women was
57 years (Table 1). Approximately 74 % of premenopausal
and 77 % of postmenopausal women in our study
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population were parous. Nearly half (45 %) of parous post-
menopausal women had age at first birth <25 years,
whereas only 24 % of parous premenopausal women had
a first birth at <25 years of age (P = 0.01, Table 1). As pre-
viously reported in this study population [17], volumetric
and area percent mammographic density measures were
higher among premenopausal as compared with postmen-
opausal women (Additional file 1: Table S1).
Relationships between IGF-I, IGFBP-3 and TDLU metrics
Median levels of IGF-I and the IGF-I:IGFBP-3 molar
ratio were higher among premenopausal women as
compared with postmenopausal women (P ≤0.001;
Table 2), whereas levels of IGFBP-3 were not signifi-
cantly different between these two groups (P = 0.44).
Correlations between TDLU count, TDLU span and
acini count were generally similar by menopausal sta-
tus, such that TDLU span and acini count were cor-
related (r >0.60; P ≤0.001), whereas TDLU count was
not significantly correlated with either acini count or
TDLU span (Additional file 2: Table S2). Correlations
observed for IGF and TDLU measures with mammo-
graphic density among pre- and postmenopausal
women were attenuated after removing the effects of
age at biopsy and BMI (Table 2).
Among all women combined, IGF-I levels in the
highest tertile versus the lowest were associated with
higher TDLU counts in fully adjusted models (RRT3vsT1 =
1.31, 95 % CI = 1.18–1.45; P-trend <0.0001; Table 3).
IGFBP-3 levels in the highest tertile versus the lowest were
Table 1 Selected characteristics of women in the BREAST
Stamp Project with benign breast disease, stratified by
menopausal status
Characteristic Premenopausal:
n = 155
Postmenopausal:
n = 73
age = 40–55
(median 47) years
age = 44–64
(median 57) years
Number Percent Number Percent Pt
Age at biopsy (years)
40–44 53 34.2 1* 1.4 <0.001
45–49 64 41.3 2 2.7
50–54 37 23.9 21 28.8
55–59 1 0.6 24 32.9
60–65 0 0 25 34.2
Race/Ethnicity
White, non-Hispanic 147 94.8 67 91.8 0.37
Other 8 5.2 6 8.2
Body mass index (kg/m2)
<25 84 54.2 32 43.8 0.34
25.0–29.9 35 22.6 21 28.8
≥30 36 23.2 20 27.4
Age at menarche (years)
≤12 56 36.1 30 41.1 0.36
13 60 38.7 21 28.8
≥14 38 24.5 21 28.8
Missing 1 0.6 1 1.4
Parity
Nulliparous 41 26.4 17 23.3 0.12
1 13 8.4 14 19.2
2 65 41.9 29 39.7
≥3 36 23.2 13 17.8
Age at first birth (years)
<25 37 23.9 33 45.2 0.01
25–29 44 28.4 14 19.2
≥30 33 21.3 9 12.3
Oral contraceptive use
Never 23 14.8 10 13.7 0.82
Ever 132 85.2 63 86.3
Type of menopause
Natural ~ ~ 53 72.6 ~
Surgical ~ ~ 3 4.1
Type unknown ~ ~ 17 23.3
Age at menopause (years)
≤45 ~ ~ 21 28.8 ~
46–49 ~ ~ 13 17.8
50–52 ~ ~ 19 26
≥53 ~ ~ 13 17.8
Unknown ~ ~ 7 9.6
Table 1 Selected characteristics of women in the BREAST
Stamp Project with benign breast disease, stratified by
menopausal status (Continued)
Any menopausal hormone therapy usea
Never 135 87.1 49 67.1 <0.001
Ever 19 12.3 24 32.9
Missing 1 0.6 0 0
Cigarette smoking (100+ cigarettes/lifetime)
Never 83 53.5 28 38.4 0.07
Former 55 35.5 31 42.5
Current 10 6.5 10 13.7
Missing/Unknown 7 4.5 4 5.5
Family history of breast cancerb
0 114 73.5 52 71.2 0.96
≥1 41 26.5 19 26
Missing 0 0 2 2.7
aData on any use of menopausal hormone therapy (MHT) missing for one
premenopausal woman, and current MHT use missing for one postmenopausal
woman who reported ever use. bWomen with at least one first degree relative
with a diagnosis of breast cancer. Pt is the value for testing for differences in
distribution by menopausal status using the chi square (Χ2) test or Fisher's exact
test when the number for a category was <5. *This woman experienced
natural menopause
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Table 2 Distribution of IGF levels and TDLU characteristics among women with benign breast disease, stratified by menopausal status
All women (n = 228) Premenopausal (n = 155) Postmenopausal (n = 73)
Median Range Correlation
with density, r
Adj. correlation
with density, r
Median Range Correlation
with density, r
Adj. correlation
with density, r
Median Range Correlation
with density, r
Adj. correlation
with density, r
P valuea
IGF measures
IGF-I (ng/ml) 116.15 20.68–250.85 0.08 −0.11 119.4 55.69–250.85 0.0001 −0.11 110.87 20.68–213.43 −0.05 −0.09 0.001
IGFBP-3 (ng/ml) 3451.25 1165.0–4926.5 −0.22** −0.14* 3419.5 1784.5–4926.5 −0.25** −0.13 3467 1165.0–4878.5 −0.18 −0.12 0.44
IGF-I:IGFBP-3 Molar ratio 0.122 0.062–0.268 0.27** −0.03 0.13 0.071–0.074 0.20* −0.05 0.11 0.062–0.189 0.08 −0.01 0.0001
Lobular involution Measures
TDLU countb 4 0–100 0.22* 0.02 5 0–100 0.21* 0.005 3 0–79 0.14 0.02 0.16
Median TDLU span, μm 266 78–1030 0.17* 0.08 292 78–1030 0.14 0.08 202 83–568 −0.17 −0.001 0.0001
Median category of acini
counts per TDLU
1 1–6 0.09 0.03 1 1–6 0.11 0.04 1 1–5 −0.10 −0.008 0.35
Correlation between insulin-like growth factor (IGF) and involution measures (continuous) with percent volumetric mammographic density was calculated using Spearman partial rank-order correlation. Adjusted (Adj.)
correlation was calculated after removing the effects of age and body mass index. *P <0.05, **P <0.001. aP values comparing levels of IGFs for premenopausal and postmenopausal women were calculated
using Kruskal–Wallis rank test. bTerminal duct lobular unit (TDLU) count refers to numbers of TDLUs per unit of tissue area. r Spearman rho, IGFBP-3 insulin-like growth factor binding protein-3
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associated with lower TDLU counts (RRT3vsT1 = 0.88, 95 %
CI = 0.80–0.96; P-trend = 0.009). IGF-I:IGFBP-3 ratio
levels in the highest tertile versus the lowest were as-
sociated with higher TDLU counts (RRT3vsT1 = 1.84,
95 % CI = 1.65–2.06; P-trend <0.0001; Table 3). Re-
sults for postmenopausal women were similar to
those for all women, although effects for IGFBP-3
(RRT3vsT1 = 0.56, 95 % CI = 0.45–0.70; P-trend <0.0001)
and the IGF-I:IGFBP-3 ratio (RRT3vsT1 = 2.78, 95 % CI =
2.14–3.62; P-trend <0.0001; Table 3) were stronger. In
contrast, only IGF-I:IGFBP-3 ratio levels in premeno-
pausal women were associated with higher TDLU counts
(RRT3vsT1 = 1.17, 95 % CI = 1.04–1.32; P-trend = 0.01).
IGF-I and IGFBP-3 and their ratio were not signifi-
cantly related to TDLU span or number of acini per
TDLU (Additional file 3: Table S3 and Additional
file 4: Table S4).
Findings from sensitivity analyses restricted to pre-
menopausal women with available hormone data (n = 86)
were consistent with those observed among all premeno-
pausal/perimenopausal women combined, such that those
in the highest tertile of IGF-I:IGFBP-3 ratio levels had
higher TDLU counts (data not shown). In addition, patterns
of association between IGF-I or IGFBP-3 and TDLU counts
were similar to and somewhat stronger than those reported
in Table 3, following mutual adjustment for IGFBP-3 and
IGF-I, respectively (Additional file 5: Table S5).
Relationships between IGF-I or IGFBP-3, and TDLU count,
stratified by mammographic density
IGFBP-3 was inversely correlated with mammographic
density and the IGF-I:IGFBP-3 ratio was positively
correlated with mammographic density, but only sig-
nificantly so among premenopausal women (r = –0.22
and r = 0.27, respectively; P <0.05; Table 2). Similarly,
TDLU count was positively correlated with mammo-
graphic density, particularly among premenopausal
women (Table 2). These associations were attenuated
after adjustment for age and BMI (Table 2). Examination
of the relationship between TDLU count and circulating
IGF levels by tertiles of mammographic density revealed
differences in the strength of the association for women
across the density spectrum. As shown in Fig. 1a, among
premenopausal women a positive association between the
Table 3 Associations between IGF levels and TDLU count among women with benign breast disease, overall and stratified by
menopausal status
All women Premenopausala Postmenopausalb
IGF measurec Number RR (95 % CI) Number RR (95 % CI) Number RR (95 % CI)
IGF-I
Tertile 1 (ref.) 76 1 52 1 25 1
Tertile 2 76 1.12 (1.01–1.23) 52 0.95 (0.85–1.06) 24 1.02 (0.83–1.26)
Tertile 3 76 1.31 (1.18–1.45) 51 1.00 (0.90–1.13) 24 1.26 (1.06–1.50)
P-trend <0.0001 0.89 0.009
IGFBP-3
Tertile 1 (ref.) 74 1 52 1 24 1
Tertile 2 76 1.03 (0.94–1.13) 52 0.94 (0.84–1.05) 24 0.57 (0.46–0.71)
Tertile 3 76 0.88 (0.80–0.96) 51 1.00 (0.90–1.11) 24 0.56 (0.45–0.70)
P-trend 0.009 0.99 <0.0001
IGF-I:IGFBP-3 molar ratio
Tertile 1 (ref.) 75 1 52 1 24 1
Tertile 2 76 1.44 (1.29–1.60) 52 1.14 (1.01–1.28) 24 1.69 (1.28–2.23)
Tertile 3 75 1.84 (1.65–2.06) 51 1.17 (1.04–1.32) 24 2.78 (2.14–3.62)
P-trend <0.0001 0.01 <0.0001
Terminal duct lobular unit (TDLU) count refers to numbers of TDLUs per unit of tissue area. Relative risk (RR) and 95 % CI were estimated using zero-inflated Poisson
regression analysis. Analyses among all women were adjusted for covariates included in both the premenopausal and postmenopausal women. P value for trend
(P-trend) was calculated using the Wald test. aFully adjusted models for premenopausal women included body mass index (BMI), age at first birth, percent fat on the
tissue slide and age at biopsy. bFully adjusted models for postmenopausal women included covariates in premenopausal women in addition to age at menarche
and an interaction term for BMI and percent fat on the tissue slide. Note: analyses of insulin-like growth factor binding protein-3 (IGFBP-3) and the molar ratio in
postmenopausal women and all women combined were additionally adjusted for age at menarche. Two women, one premenopausal and one postmenopausal,
were missing data on this risk factor and were not included. cTertiles (T) for all women: insulin-like growth factor (IGF-I) (T1, <103; T2, 103 to <128; T3, 128+ ng/ml);
IGFBP-3 (T1, <3,110; T2, 3,110 to <3,677; T3, 3,677+ ng/ml); molar ratio (T1, <0.113; T2, 0.113 to <0.133; T3, 0.133+). Tertiles for premenopausal women: IGF-I (T1, <107;
T2, 107 to <132.3; T3, 132.3+ ng/ml); IGFBP-3 (T1, <3,079; T2, 3,079 to <3,668; T3, 3,668+ ng/ml); molar ratio (T1, <0.119; T2, 0.119 to <0.140; T3, 0.140+). Tertiles for
postmenopausal women: IGF-I (T1, <93; T2, 93 to <122; T3, 122+ ng/ml); IGFBP-3 (T1, <3,214; T2, 3,214 to <3,838; T3, 3,839+ ng/ml); molar ratio (T1, <0.102;
T2, 0.102 to <0.1205; T3, 0.1205+).
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IGF-I:IGFBP-3 ratio and TDLU count was observed for
women in the highest tertile of mammographic density
(P-int = 0.006). For postmenopausal women (Fig. 1b),
mammographic density modified all IGF associations
with TDLU count; associations were strongest among
those with higher mammographic density (IGF-I, P-
int <0.0001; IGFBP-3, P-int = 0.02; and IGF-I:IGFBP-3
ratio, P-int <0.0001). Patterns of association were
similar, though stronger, following mutual adjustment
for IGFBP-3 and IGF-I (Additional file 6: Figure S1).
Discussion
Our study demonstrates that elevated IGF-I:IGFBP-3
ratios among women with biopsy-proven benign
breast disease were associated with higher TDLU
counts, a measure of decreased TDLU involution,
which has been linked to increased breast cancer risk.
The associations between the IGF-I:IGFBP-3 ratio and
TDLU count were strongest among postmenopausal
women who had high mammographic density. In con-
junction with mechanistic studies performed in ani-
mal models, our results suggest that studies assessing
IGF levels and TDLU involution as markers of breast
cancer risk are warranted. In addition, our findings
further highlight the influence of the growth factor
milieu on breast tissue architecture and pliability in
the carcinogenic process.
Relationships between IGF-I, IGFBP-3 and the ratio of
the two with TDLU measures differed by menopausal
status. TDLU count was associated with IGF-I, IGFBP-3
and their ratio in postmenopausal women; however, only
the IGF-I:IGFBP-3 ratio was associated with TDLU
count in premenopausal women. The degree to which
circulating hormones and growth factors interact within
the tissue microenvironment [32–34] may partially ac-
count for the observed differences in associations by
menopausal status. Moreover, as TDLU involution typic-
ally increases with age [6] and IGF-I decreases with age
[35], future, larger studies of pre-, peri- and postmeno-
pausal women will be important for gaining further
insight into how the IGF system exerts its effects on
breast architecture and tumor development across the
life course.
Consistent with our findings, prior work suggests that
increased mammographic density is associated with less
TDLU involution [14, 16], and in multivariable risk
models, having no or partial lobular involution has been
associated with increased breast cancer risk, independ-
ent of mammographic density [1]. Several studies have
also linked high levels of circulating IGF-I and low levels
a b
Fig. 1 Association between insulin-like growth factor (IGF) levels and terminal duct lobular unit (TDLU) count among women with benign breast
disease stratified by mammographic density. The association between levels of IGF proteins including IGF-I, IGF binding protein-3 (IGFBP-3) and
the IGF-I:IGFBP-3 molar ratio, and TDLU count (modeled continuously) stratified by mammographic density are shown for a premenopausal
women adjusted for age at biopsy, body mass index (BMI), age at first birth and percent fat on the tissue slide; and b postmenopausal women
adjusted for age at biopsy, BMI, age at first birth and percent fat on the tissue slide. Analysis of IGFBP-3 and the molar ratio, but not IGF-I, in
postmenopausal women was further adjusted for age at menarche, with the exception of the stratum for the highest tertile of mammographic
density. Relative risk (RR) and 95 % confidence intervals (CI) were estimated using zero-inflated Poisson regression analysis, the outcome for the
analysis was TDLU count (modeled continuously) and the independent variable was tertile of IGF-measure. These analyses were stratified by
tertile of percent volumetric mammographic density; density tertiles were as follows: premenopausal: T1, <30.5 %; T2, 30.5 to <53 %; T3≥ 53.3 % and
postmenopausal: T1, <22 %; T2, 22 to <33.3 %; T3, ≥33.3 %. P-int = P value for interaction
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of IGFBP-3 to elevated mammographic density among
pre- [26, 36, 37] and postmenopausal [38] women. How-
ever, most studies have been null among postmeno-
pausal women ([39–41]; reviewed in [42]). Our findings
are consistent with this literature in that we observed
correlations between IGFs and mammographic density
only among premenopausal women in our study
population. Notably, we found that mammographic
density modified associations with TDLU count for
the IGF-I:IGFBP-3 ratio in premenopausal women
and for all IGF measures in postmenopausal women,
such that associations were strongest among those
with higher mammographic density.
Assessing whether adding IGF levels, TDLU involution
and mammographic density enhance prediction of devel-
oping breast cancer among women with biopsy-proven
benign breast disease may be useful. We hypothesize a
parallel role for the IGF system among women, whereby
this pathway and its related networks influence breast
cancer risk by altering parenchymal composition,
organization and function (Fig. 2). Interestingly, local ex-
pression of IGF-I in the mammary gland of transgenic
mice was found sufficient to stimulate increased milk
yield, providing additional evidence in support of this
hypothesis [9]. Further, given that mammographic dens-
ity is a strong breast cancer risk factor reflecting the
fibroglandular content of the breast [15, 42], the IGF
system may link the associations between mammo-
graphic density, TDLU involution and breast cancer risk
(Fig. 2).
To our knowledge, we are the first to demonstrate
an association between circulating IGF levels and
TDLU count as a measure of lobular involution. Rice
and colleagues found that higher IGF-I levels and
IGF-I:IGFBP-3 ratios were associated with less invo-
luted TDLU categories, based on visual evaluation,
which in turn was related to increased risk of breast
cancer among women with benign breast disease [5].
In a transgenic mouse model, the IGF system has
been shown to be effective in inhibiting involution of
the lactating mammary gland [43]. These results,
along with the current report, suggest a role for IGFs
in TDLU involution and breast cancer risk.
We did not identify any significant associations be-
tween IGFs and TDLU span or acini count per TDLU,
two additional measures of TDLU involution. TDLU
span and acini count are highly correlated, whereas
TDLU count is weakly correlated with either measure.
Thus, TDLU span and acini count may reflect biological
processes distinct from TDLU counts. Alternatively, as-
sociations may vary with TDLU metrics secondary to
measurement and analysis. In prior analyses [6, 25], we
Fig. 2 Hypothesized association between insulin-like growth factor (IGF) levels, terminal duct lobular unit (TDLU) involution, mammographic
density and breast cancer risk. Circulating IGF levels in the breast may influence the parenchymal composition and organization leading to
alterations in the surrounding epithelial tissue whereby higher levels of IGF-I and IGF-I:insulin-like growth factor binding protein-3 (IGFBP-3)
ratio result in higher TDLU counts, decreased TDLU involution and presumably increased breast cancer risk. On the other hand, higher
IGFBP-3 and lower circulating levels of IGF-I:IGFBP-3 ratio may permit the involution process to proceed, resulting in age-appropriate TDLU
involution and decreased risk of breast cancer. Higher mammographic density, a strong breast cancer risk factor, may modify the IGF/involution
relationship such that IGF may exert its greatest influence on TDLU involution among women with the highest mammographic density.
Red lines (top H&E image) (higher TDLU count) indicate the span of the TDLU as measured by an electronic ruler
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have found that risk factor associations vary by the three
TDLU metrics that we analyzed. One hypothesis is that
TDLU span and acini content may vary more over time,
whereas total loss of TDLUs could represent a relatively
irreversible alteration. In addition, in highly involuted
breast tissue, TDLUs may be absent, precluding assess-
ment of span or acinar content in these individuals.
Using ZIP regression allowed us to account for the num-
ber of samples with zero TLDU counts, which is import-
ant as such specimens may represent a profound degree
of TDLU involution, although sampling represents an-
other possible explanation in some women.
A major strength of our study was the utilization of
highly reproducible measures of TDLU involution. A re-
cent study found that TDLU counts were positively as-
sociated with number of live births and family history of
breast cancer, and inversely associated with older age at
menarche among postmenopausal women [6]. Also, ana-
lyses within the Mayo Benign Breast Disease Cohort
found a stepwise increase in breast cancer risk with in-
creasing numbers of acini per lobule [4]. Findings from
the Mayo Cohort noting strong intra-woman concord-
ance of subjectively assessed involution, measured in
four quadrants of both breasts of 15 women who had
undergone prophylactic mastectomy [44], also support
the notion that measures of TDLU involution reflect a
global process occurring throughout the breast and are
general markers of breast cancer risk [3, 16]. These data
in concert with our findings provide support for devel-
oping improved metrics of TDLU involution and its
assessment as a potential intermediate measure of breast
cancer risk.
A limitation of our study is that circulating levels of
growth hormones were used, and analysis of tissue levels
might prove more informative. In an analysis of healthy
women, plasma and breast tissue levels of IGF-I and
IGFBP-3 were not associated; however, breast cancer risk
factors associated with plasma IGF-I and IGFBP-3 were
similarly associated with breast concentrations of IGF-I
and IGFBP-3 [45]. Another limitation of our study is
that we were unable to stratify our data by menstrual
cycle phase because of small numbers within each cat-
egory, and thus, could not adjust for potential fluctua-
tions in IGF-I levels over the menstrual cycle [46].
However, TDLU structure and mammographic density
are unlikely to vary greatly during menstrual cycles
[6, 47]. Similarly, we were unable to model benign
diagnoses more specifically because of limited sample
size. These limitations would likely have biased our
findings toward the null. Finally, given the variation
in IGF-I and IGFBP-3 levels by racial/ethnic groups
[48–51], our findings may not apply to non-white
women, as white women comprised nearly all partici-
pants in this study population.
Conclusion
In summary, we demonstrated that circulating levels of
serum IGF-I and IGFBP-3 are associated with TDLU
count among women with benign breast disease, and that
the strongest associations are found among women who
have high mammographic density. Our findings contrib-
ute to the body of knowledge that supports the evaluation
of TDLU involution and mammographic density as pos-
sible intermediate endpoints in breast carcinogenesis.
Expanding this analysis to a study of breast cancer risk
may further contribute to an improved understanding of
the role of TDLU involution, or lack thereof, in the mam-
mary carcinogenic process, which could have value for im-
proving risk prediction and prevention.
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